


SI-BONE Corporate Overview

August 2026



Forward-Looking Statements

The statements in this press release regarding expectations of future events or results, including SI-BONE's expectations of continued revenue and procedure growth and financial outlook, are "forward-looking" statements. These forward-looking statements are based on SI-BONE's current expectations and inherently involve significant risks and uncertainties. These risks include SI-BONE's ability to introduce and commercialize new products and indications, SI-BONE's ability to maintain favorable reimbursement for procedures using its products, the impact of any future economic weakness or deterioration in economic conditions as a result of tariffs and retaliation by U.S. trading partners on the ability and desire of patients to undergo elective procedures including those using SI-BONE's products, SI-BONE's ability to manage risks to its supply chain, future capital requirements driven by new surgical systems requiring instrument tray and implant inventory investment, and the pace of the re-normalization of the healthcare operating environment including the ability and desire of patients and physicians to undergo and perform procedures using SI-BONE's products. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these and other risks and uncertainties, many of which are described in SI-BONE's most recent filings on Form 10-K and Form 10-Q, and SI-BONE's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov), especially under the caption "Risk Factors." SI-BONE does not undertake any obligation to update forward-looking statements and expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.



Business Update

Second Quarter 2026: Key Highlights

Accelerating, Broad-Based Growth

- 15.2% worldwide revenue growth to \$56.0 million
- 14.7% U.S. revenue growth to \$53.2 million
- 19% growth in U.S. active physicians

Disciplined Execution, Expanding Profitability

- 79.5% gross margin
- \$2.2 million in trailing-12-month territory productivity
- \$2.8 million in positive AEBITDA ⁽²⁾
- \$1.3 million net cash generated ⁽³⁾

510(k) Submitted for Third Breakthrough Device

Targeting 4Q launch

New DRG Family Finalized

Higher payment for complex spinal fusion procedures incorporating Granite ⁽¹⁾

Record 1,715 Active Physicians

+275 users

Positive AEBITDA

~178% Improvement

Note: As of August 3, 2026

Note: All comparisons are versus Second Quarter 2025 unless otherwise noted


1. Note: Effective October 1, 2026

2. SI-BONE uses Adjusted EBITDA as a proxy for profitability. AEBITDA is a non-GAAP financial measures that excludes from net loss the effects of interest income, interest expense, depreciation and amortization and stock-based compensation.


3. Compared to First Quarter of 2026

Strong Q2 momentum across revenue and volume


2Q WW REVENUE (\$M)



2Q US REVENUE (\$M)




U.S. 2Q PROCEDURE VOLUME



Note: As of August 3, 2026
Note: Rounded for presentation purposes

Record Physician Engagement Driving Procedure Demand




22 consecutive quarters of double-digit U.S. physician growth

15% increase in physicians performing multi-modality procedures

Note: As of August 3, 2026

Growing Profitability and Robust Liquidity



Growing profitability

- **~180% increase** in AEBITDA

Robust liquidity

- **\$145.9 million** in cash and equivalents
- **Positive cash flow** from operations in the quarter

Note: As of August 3, 2026

SI-BONE uses Adjusted EBITDA as a proxy for profitability. AEBITDA is a non-GAAP financial measures that excludes from net loss the effects of interest income, interest expense, depreciation and amortization and stock-based compensation. Any comparison is to prior year period, unless stated otherwise.

Long-Term Business Drivers

Platform Set-up to Deliver Strong Revenue Growth and Operating Leverage

Innovation

Build differentiated portfolio

Develop disruptive solutions that improve procedural outcomes for patients with compromised bone

Physician Engagement

Drive penetration and adoption

Leverage training and expanding portfolio to drive physician growth and density

Develop clinical data to drive physician adoption

Commercial Execution

Accelerate market expansion

Grow direct commercial footprint

Expand agent network and strategic commercial partnerships to broaden platform access

Operational Excellence


Expand Profitability

Increase revenue per territory

Optimize cost and increase utilization of surgical capacity

>\$3B Opportunity | Breakthrough Products | Differentiated Health Economics | Scalable Infrastructure | Strong Liquidity

Updated 2026 WW Revenue Guidance (\$M)



	Guidance FY26 (Current)	Guidance FY26 (Prior)
Revenue	\$231.0 - \$233.0 million	\$230.0 - \$233.0 million
Revenue growth (y/y)	~15% - 16% (implied)	~14% - 16% (implied)
Gross Margin	~79%	~79%
Operating Expenses (at mid-point of guidance)	~12.0%	~12.5%

Note: As of August 3, 2026

Differentiated Portfolio Complemented By Strong Fundamentals

Robust Data

190+ published papers
4 Randomized Controlled Trials

Reimbursement Advantage

New DRGs Finalized for inpatient iFuse Bedrock Granite procedures
NTAP for iFuse TORQ TNT

Large, Underpenetrated Markets

470,000 annual target procedures, for a total annual opportunity > \$3.5 billion
<10% total addressable market penetrated

Strong Execution Track Record

5 Years of double-digit U.S. active physician base growth
Third Breakthrough Device 510(k) Submitted

Proven Operational Excellence

\$0.8M Positive cash flow from operations in the second quarter
~2.0x Operating Leverage in the second quarter

>\$3B Opportunity | **Breakthrough** Products | **Differentiated** Health Economics | **Scalable** Infrastructure | **Strong** Liquidity

Note: As of August 3, 2026

Operating leverage defined as revenue growth divided by operating expenses growth



Company Overview

Market Leading Platform For Compromised Bone Procedural Solutions



Innovation

3 Breakthrough Designated Devices
82 WW Patents



Evidence

4 Randomized Controlled Trials ¹⁻⁴
190+ Peer-reviewed Publications ⁵



Education

1,715 Active US Physicians ^{6,7}
~150,000+ Procedures Performed ⁸



Commercialization

93 Territory Managers
400+ CSS and Agents

>\$3B Opportunity | **Breakthrough** Products | **Differentiated** Health Economics | **Scalable** Infrastructure

Note: As of August 3, 2026

1. Polly DW, et al. *Int J Spine Surg*. 2016 Aug 23;10:28. [INSITE 2yr]
2. Dengler J, et al. *J Bone Joint Surg Am*. 2019;101(5):400-11. [IMIA 2yr]
3. Shannon SF, et al. *Injury*. 2025 May 31;56(8):112462. [SAFFRON]
4. Polly DW, et al. *World Neurosurg*. 2024 Jul;187:e15-e27. [SILVIA 2yr]

5. si-bone.com/results
6. Physicians who performed a procedure in the quarter.
7. Physicians encompasses surgeons and interventionalists.
8. As of August 3, 2026. Procedures worldwide with SI-BONE products since inception of the company.

Large Addressable Markets with Attractive Fundamentals

~470,000

**Target U.S. Annual
Procedures¹**

> \$3.5 Billion

**Total U.S. Addressable
Market¹**

Pelvic Trauma⁵

60,000

\$0.3 Billion

Sacropelvic Fixation

Adult Deformity³ + Degenerative Spine⁴

130,000

\$1.0 Billion

SI Joint Dysfunction²

280,000

\$2.4 Billion

**Target U.S. Annual
Procedures**

**Total U.S. Annual
Addressable Market**

1. Management estimate for existing and potential products in 2025. Total addressable market defined as target case volume x Current ASP.
2. Sources: Jensen M, et al. Magnetic Resonance Imaging of the Lumbar Spine in People Without Back Pain. *N Engl J Med*. 1994;331:69-116.; Bernard 1987, Schwarzer 1995, Maigne 1996, Irwin 2007, Sembrano 2009; INSITE RCT data: 5 years in pain and 31% of patients screened were eligible for surgery.; 4. 1.2M therapeutic injections per year with average patient in 5 years of pain = ~280K cases
3. 30K target procedures: 70K Deformity Procedures (Source: U.S. 2020 Wallstreet Report) less Pediatric Procedures (Source: www.hopkinsmedicine.org)
4. 100K target procedures: 400K Lumbar Fusion Procedures (Source: 2020 Wallstreet Report); 25% procedures are L4-S1 and L5-S1 (Source: Orthopedic Network News, October 2020)
5. US Fragility FX TAM: 136K Incidence x 40% surgical candidates = 54K; High Energy FX TAM: 6K Pelvic Trauma Surgeries = 6K Source: Management estimates based on internal research; Melton, et al. (1981). Epidemiologic features of pelvic fractures. *Clin Orthop Relat Res*; Rommens, et al. (2017). Fragility fractures of the pelvis. *JBUS*; Demetriades, et al. (2002). Pelvic fractures with abdominal injuries. *J Am Coll Surg*.


Three Large Unmet Clinical Needs in Sacropelvic Conditions

SI Joint Dysfunction

15-30% Chronic LBP is SI Joint¹⁻⁵

~40% Symptomatic Post Lumbar Fusion⁶⁻⁹

High Burden of Disease¹⁰




- Bernard 1987
- Schwarzer 1995
- Maigne 1996
- Irwin 2007
- Sembrano 2009
- Katz 2003
- Maigne 2005
- DePalma 2011
- Liliang 2011
- Cher 2014

Pelvic Trauma

Older Population Fragility FXs Increasing¹¹⁻¹³

78% of Insufficiency FXs treated Non-surgically¹⁴

Increased Mortality Risk, Downward Spiral¹⁵⁻¹⁸




- Burge 2007
- Rommens 2021
- Lyders 2010
- Medicare ICD-10 Code Search (Jun 2020)
- Bakker 2018
- Ramser 2022
- Briggs 2023
- Babayev 2000

Spinopelvic Fixation

24% Rate of Pelvic Fixation Failure in ASD Surgery¹⁹

28% SI Joint Issues Post Spinal fusion²⁰

More Levels Fused Increases SI Joint Pain²¹



- Eastlack 2022
- Manzetti 2023
- Unoki 2016
- Ivanov 2009

Innovation Driven Differentiated Platform

iFuse INTRA® & INTRA X® iFuse INTRA Ti™

*Intra-articular
Stabilization & Fusion*

Small surgical profile

Intra-articular placement

Designed to improve SI joint stability^{1*}



iFuse TORQ® iFuse TORQ TNT®

*Cutting-Edge Pelvic Fixation
& Fusion; and Fragility Fractures*

TORQLock™ reduces toggle

EZDrive® decreases surgical steps

IntelliHarvest® self-harvests bone




iFuse 3D™ iFuse

*Market Leader in
SI Joint Fusion*

6x > rotational resistance vs. screws^{2*}

3 RCTs, 140+ Peer-reviewed studies^{3,6}

Promotes osseointegration^{4*}



iFuse Bedrock Granite®

*Breakthrough Fixation,
Fusion, Foundation*

Higher pull-out strength vs. Solera^{5*}

Facilitates osseointegration

Largest neck on the market



SI Joint Dysfunction

Pelvic Trauma

Sacropelvic Fixation

1. SI-BONE Technical Study 301310-TS.
2. SI-BONE Technical Study 300610-TS.
3. Polly – IJSS 2016; Dengler – JBJS Am 2019; <https://si-bone.com/results>
4. MacBarb – IJSS 2019 (Part 2).
5. SI-BONE Technical Study 301098-TS.
6. Polly DW, et al. *World Neurosurg.* 2024 Jul;187:e15-e27. [SILVIA 2yr]

* Biomechanical and animal studies not necessarily indicative of human clinical outcomes.


Patent Protected Differentiated Platform

- 82 issued patents: U.S. (51), OUS (31)

- 46 pending patents: U.S. (28), OUS (18)


- iFuse 3D™ implant patents until Sept 2035
- Triangular broach instrument patent until Feb 2034
- iFuse implant patent until August 2028

INSTRUMENT



Triangular broach instrument and the methods of using the instrument


3-D TECHNOLOGY



Rectilinear profile, longitudinal struts, and struts connecting the longitudinal struts


- iFuse TORQ® implant patent until Feb 2041
- iFuse Bedrock Granite® implant patent until Feb 2039

iFuse Bedrock Granite




Inner shank with external distal threads and an outer sleeve with threads, surface growth features, and fenestrations

iFuse TORQ



Helical threads, porous network of struts disposed between the threads, and the porous height is less than the major thread diameter



Portfolio Overview

Sacroiliac Joint Dysfunction Treatments

Non-surgical Management

Medications
(NSAIDS,
opiates, etc.)



Physical



**External
Support**
(SI Joint
Belt)



**Therapeutic
SI Joint
Injections**
(anesthetic &



**Radiofrequency
Ablation**




Procedures

**Bone Allograft
SI Joint
Stabilization
& Fusion**




**MIS
SI Joint Fusion**



iFuse INTRA Ti™: Intra-Articular Titanium Implant



Differentiated Technology



Intra-articular Placement



iFuse Lattice Technology



Fenestrations



Cutting Blades

Competitive Advantages

- Cortical Piercing
- Intra-articular placement
- Single Use Instrument Kit

Access/Reimbursement

- FDA Cleared:** February 2026
- Uses Existing CPT Code:** 27279

iFuse TORQ[®]: *Cutting-Edge Pelvic Fixation and Fusion*[™]

Large, Adjacent Market¹

>\$300 million Pelvic Trauma opportunity

~120K Sacral Fragility fracture incidence / yr.

Differentiated Technology

FuSlon 3D[™] Surface for Osseointegration

IntelliHarvest[®] Technology self harvests host bone

Competitive Advantages

TORQLock[™] Threads²

10x rotational resistance on insertion vs. trauma screws




1. Based on internal estimates.
2. Internal clinical reports. Data on file.


iFuse Bedrock Granite®: *Fixation. Fusion. Foundation.*™



Differentiated Technology



Microporous Lattice Surfaces



Macroporous Fenestrations
IntelliHarvest® Cutting Flutes



OMNISCapture™ Tulip & Set Screw

Large, Adjacent Market

~\$1 billion Adult Spinal Deformity and Degenerative Spine pelvic fixation opportunity¹
Additional application for 9.5 diameter implant in S1 trajectory and pediatric deformity²

Competitive Advantages

Breakthrough Device Designation by the FDA
New DRG Family established effective October 1, 2026

1. Based on management estimate of total addressable market for existing and potential products in 2024.


2. 510(k) Clearance – K233508 (Jan 2024)

iFuse TORQ TNT®: Pelvic Bone Density-Driven Design



FDA Clearance
September 2024

- Through ‘N Through™ (“TNT”)¹
- FDA Breakthrough Device Designation²
- Pelvic fragility fracture fixation
- Pelvic-specific 8.7mm diameter
- 3D-printed porous lattice surface designed for osseointegration



CMS FY2026 IPPS New Technology Add-On Payment (“NTAP”) of up to \$4,136

1. The first 3D-printed, porous threaded implant with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium.

2. The FDA determined iFuse TORQ TNT has the potential to provide more effective fixation of pelvic fragility fractures than the current standard of care, cannulated screws.

Disclosures

The **iFuse Bedrock Granite® Implant System** is intended for sacroiliac joint fusion in skeletally mature patients for the following conditions:

- Sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months.
- To augment immobilization and stabilization of the sacroiliac joint in patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion.
- Acute, non-acute, and non-traumatic fractures involving the sacroiliac joint

When connected to compatible pedicle screw systems with 5.5- or 6.0-mm posterior rods made from either titanium alloy or cobalt chrome alloys, the iFuse Bedrock Granite Implant System is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to thoracolumbosacral fusion for the following acute and chronic instabilities or deformities of the thoracic, lumbar, and sacral spine:

- Degenerative disc disease (DDD) as defined by back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies
- Spondylolisthesis
- Trauma (i.e., fracture or dislocation)
- Spinal stenosis
- Deformities or curvatures (i.e., scoliosis, kyphosis, and/or lordosis)
- Spinal tumor
- Pseudarthrosis
- Failed previous fusion

When connected to compatible pedicle screw systems with 5.5- or 6.0-mm posterior rods made from either titanium alloy or cobalt chrome alloys, the iFuse Bedrock Granite Implant System is intended to provide immobilization and stabilization of spinal segments in skeletally immature patients as an adjunct to thoracolumbar fusion for the treatment of progressive spinal deformities (i.e., scoliosis, kyphosis, or lordosis) including idiopathic scoliosis, neuromuscular scoliosis, and congenital scoliosis, as well as the following conditions: spondylolisthesis/spondylolysis, fracture caused by tumor and/or trauma, pseudarthrosis, and/or failed previous fusion. These devices are to be used with autograft and/or allograft. Pediatric pedicle screw fixation is limited to a posterior approach.

The iFuse Bedrock Granite Navigation instruments are intended to be used with the iFuse Bedrock Granite Implant System and the Medtronic StealthStation System to assist the surgeon in precisely locating anatomical structures in iFuse Bedrock Granite Implant System procedures, in which the use of stereotactic surgery may be appropriate, and where reference to a rigid anatomical structure, such as the pelvis or vertebra, can be identified relative to the acquired image (CT, MR, 2D fluoroscopic image or 3D fluoroscopic image reconstruction) and/or an image data-based model of the anatomy.

The Granite iGPS instruments and iGPS Drill Bits are compatible with Globus ExcelsiusGPS® Instrument Trackers and intended to be used with the iFuse Bedrock Granite Implant System and the Globus ExcelsiusGPS® Robotic Navigation System (including the Globus Excelsius3D® Imaging System), which is intended for use as an aid for precisely locating anatomical structures and for spatial positioning and orientation of an instrument holder or guide tube to be used by surgeons for navigating and/or guiding compatible surgical instruments in open or percutaneous procedures provided that the required fiducial markers and rigid patient anatomy can be identified on CT scans or fluoroscopy.

Use of the iGPS instruments is limited to use only with the 9.5 mm and 10.5 mm iFuse Bedrock Granite implants.

For Use for indications, contraindications, warnings, and precautions at [si-bone.com/label](https://www.si-bone.com/label).

There are potential risks associated with iFuse procedures. They may not be appropriate for all patients, and all patients may not benefit. For information about the risks, visit [si-bone.com/risks](https://www.si-bone.com/risks).

Disclosures

The **iFuse TORQ®** Implant System is indicated for:

- Sacroiliac joint dysfunction including sacroiliac joint disruption and degenerative sacroiliitis.
- Augmenting immobilization and stabilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion.

The iFuse TORQ Implant System is also indicated for fracture fixation of the pelvis, including acute, non-acute, and non-traumatic fractures.

The iFuse TORQ Navigation instruments are intended to be used with the iFuse TORQ Implant System to assist the surgeon in precisely locating anatomical structures in iFuse TORQ Implant System procedures, in which the use of stereotactic surgery may be appropriate, and where reference to a rigid anatomical structure, such as the pelvis or vertebra, can be identified relative to the acquired image (CT, MR, 2D fluoroscopic image or 3D fluoroscopic image reconstruction) and/or an image data based model of the anatomy. iFuse TORQ Navigation instruments are intended to be used with the Medtronic® StealthStation® System.

The TORQ iGPS instruments and iGPS Drill Bits are compatible with Globus ExcelsiusGPS® Instrument Trackers and intended to be used with the iFuse TORQ Implant System and the Globus ExcelsiusGPS® Robotic Navigation System (including the Globus Excelsius3D® Imaging System), which is intended for use as an aid for precisely locating anatomical structures and for spatial positioning and orientation of an instrument holder or guide tube to be used by surgeons for navigating and/or guiding compatible surgical instruments in open or percutaneous procedures provided that the required fiducial markers and rigid patient anatomy can be identified on CT scans or fluoroscopy. Use of the iGPS instruments is limited to use only with 10.0 mm and 11.5 mm fully threaded iFuse TORQ implants.

The **iFuse TORQ TNT®** Implant System is indicated for fracture fixation of the pelvis, including acute, non-acute and non-traumatic fractures.

The iFuse TORQ TNT Implant System is indicated for sacroiliac joint fusion for sacroiliac joint dysfunction including sacroiliac joint disruption and degenerative sacroiliitis.

The iFuse TORQ TNT Navigation Instruments are intended to be used with the iFuse TORQ TNT Implant System to assist the physician in precisely locating anatomical structures in iFuse TORQ TNT Implant System procedures, in which the use of stereotactic surgery may be appropriate, and where reference to a rigid anatomical structure, such as the pelvis or vertebra, can be identified relative to the acquired image (CT, MR, 2D fluoroscopic image or 3D fluoroscopic image reconstruction) and/or an image data based model of the anatomy. iFuse TORQ TNT Navigation Instruments are intended to be used with the Medtronic® StealthStation® System.

The **iFuse INTRA Ti™** Implant System is intended for fusion of the sacroiliac joint for sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months.

Healthcare professionals please refer to the Instructions For Use for indications, contraindications, warnings, and precautions at [si-bone.com/label](https://www.si-bone.com/label). There are potential risks associated with iFuse procedures. They may not be appropriate for all patients, and all patients may not benefit. For information about the risks, visit: [si-bone.com/risks](https://www.si-bone.com/risks).

Reconciliation of Adjusted EBITDA

\$ in thousands	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025
Net loss	\$ (4,088)	\$ (6,152)
Interest income	(1,332)	(1,520)
Interest expense	598	666
Depreciation and amortization	1,679	1,368
Stock-based compensation	5,979	6,658
Adjusted EBITDA	\$ 2,836	\$ 1,020

SI-BONE uses Adjusted EBITDA, a non-GAAP financial measure that excludes from net loss the effects of interest income, interest expense, depreciation, amortization, and stock-based compensation. SI-BONE believes the presentation of Adjusted EBITDA is useful to management because it allows management to more consistently analyze period-to-period financial performance and provides meaningful supplemental information with respect to core operational activities used to evaluate management's performance. SI-BONE also believes the presentation of Adjusted EBITDA is useful to investors and other interested persons as it enables these persons to use this additional information to assess the company's performance in using this additional metric that management uses to assess the company's performance.

Adjusted EBITDA should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because Adjusted EBITDA excludes the effect of items that increase or decrease the Company's reported results of operations, management strongly encourages investors to review, when they become available, the Company's consolidated financial statements and publicly filed reports in their entirety. The Company's definition of Adjusted EBITDA may differ from similarly titled measures used by others.

Reconciliation of Free Cash Flow

\$ in thousands	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
Net cash used in operating activities	\$ (1,585)	\$ (4,738)
Less:		
Purchases of Property and Equipment	(2,622)	(4,171)
Free Cash Flow	\$ (4,207)	\$ (8,909)

SI-BONE uses Free Cash Flow, a non-GAAP financial measure. Free cash flow is defined as net cash provided by operating activities less purchases of property and equipment. SI-BONE believes the presentation of free cash flow is useful to management because it allows management to more consistently analyze period-to-period financial performance and provides meaningful supplemental information with respect to core operational activities used to evaluate management's performance. SI-BONE also believes the presentation of free cash flow is useful to investors and other interested persons as it enables these persons to use this additional information to assess the company's performance in using this additional metric that management uses to assess the company's performance.

Free cash flow should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because free cash flow excludes the effect of items that increase or decrease the Company's reported results of operations, management strongly encourages investors to review, when they become available, the Company's consolidated financial statements and publicly filed reports in their entirety. The Company's definition of free cash flow may differ from similarly titled measures used by others.



Pioneering Procedural Solutions *For Compromised Bone*®

~150,000
Procedures

1,715
Active Physicians

190+
Publications

Note: As of August 3, 2026